After five years, nearly half the Lynparza-treated patients in the SOLO-1 trial remained disease-free, compared with one-fifth of those who received placebo.
The signature may be useful for guiding treatment strategy based on patients' prognoses, and with further validation, may even be useful for predicting response to specific drugs.
Senaparib is currently being studied in a Phase II trial as a monotherapy for BRCA-mutated ovarian cancer patients who have received at least two prior lines of therapy.
An analysis of societal and health system cost-effectiveness and outcomes points to the benefits of expanding pathogenic BRCA1/2 variant testing in six countries.
A case series in partnership with My Gene Counsel to highlight the challenges genetics professionals and oncologists are grappling with as genetic testing is increasingly used in patient care.
The drug, which is designed to restore normal functioning of p53, has allowed a promising proportion of TP53-mutated MDS patients to receive stem cell transplants in early trials.
With studies showing BRCA-mutated patients have a greater magnitude of benefit, oncologists grapple with complex treatment decisions in BRCA mutation-free cases.
The MAGENTA and ProGen trials showed that video-based and online education can increase the number of patients getting tested compared to traditional approaches.
